Systemic sclerosis & Raynaud's
Facial Cosmetic Therapy Use Among Patients With Systemic Sclerosis: An Australian Cohort Study
Authors' conclusion
Patients with SSc engage broadly with cosmetic therapies for both SSc-related and non-SSc-related facial changes. Most users reported subjective improvement, and few serious adverse effects were reported.
Study context
- Population
- Patients with systemic sclerosis (SSc) enrolled in the Australian Scleroderma Cohort Study at three Australian public tertiary hospitals and one private practice616 invited
- Participants
- 241 patients
- Outcome
- Engagement and perceived outcomes with facial cosmetic therapies (topical cosmeceuticals, injectables, energy-based devices or laser, surgery)
Methodological detailsquestionnaire survey, multicentre, descriptive statistics
- Questionnaire survey
- Multicentre
- Descriptive statistics
Main finding
As reported in the abstract
Engagement with facial cosmetic therapies
- Previously or currently considering a facial cosmetic therapy
- 119 (49.4%)
- Use of at least one therapy
- 55 (22.8%)
- Considered but did not proceed due to cost
- 32 (50.0%)
- Considered but did not proceed due to safety concerns
- 24 (37.5%)
- Total facial cosmetic therapies reported
- 159
- Topical cosmeceuticals
- 42.1%
- Injectable therapies
- 32.1%
- Energy-based devices or laser therapies
- 22.6%
- Surgical procedures
- 2.5%
- Performed for SSc-related facial changes
- 64.2%
- Perceived improvement (therapies)
- 116 (73.0%)
Observational data: associations, not effects.
Safety
Adverse events (per therapy)
- Therapies with adverse events
- 25 (15.7%)
- Most adverse events were mild
Original publication
Facial Cosmetic Therapy Use Among Patients With Systemic Sclerosis: An Australian Cohort Study. Arthritis Care Res (Hoboken). Published 17 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →